EPISODE · Apr 20, 2026 · 47 MIN
Private Credit Woes & Psychedelic Wins 4/20/26
from Squawk Pod · host CNBC
As concerns mount regarding the health of the private credit ecosystem, Oaktree Capital Management co-chairman Howard Marks offers perspective–and some investing advice–when it comes to private lending. Former FDA Commissioner Dr. Scott Gottlieb discusses Eli Lilly’s deal to expand its cancer treatment pipeline as well as President Trump’s executive order on therapeutic psychedelics. Plus, Kevin Warsh’s Fed Chair nomination hearing is this week, and Anthropic’s Mythos is at work within the NSA, despite being blacklisted by the US government. Steve Liesman 14:36 Howard Marks 23:54 Dr. Scott Gottlieb 41:27 In this episode: Steve Liesman, @steveliesman Andrew Ross Sorkin, @andrewrsorkin Becky Quick, @BeckyQuick Joe Kernen, @JoeSquawk Katie Kramer, @Kramer_Katie Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
What this episode covers
As concerns mount regarding the health of the private credit ecosystem, Oaktree Capital Management co-chairman Howard Marks offers perspective–and some investing advice–when it comes to private lending. Former FDA Commissioner Dr. Scott Gottlieb discusses Eli Lilly’s deal to expand its cancer treatment pipeline as well as President Trump’s executive order on therapeutic psychedelics. Plus, Kevin Warsh’s Fed Chair nomination hearing is this week, and Anthropic’s Mythos is at work within the NSA, despite being blacklisted by the US government. Steve Liesman 14:36 Howard Marks 23:54 Dr. Scott Gottlieb 41:27 In this episode: Steve Liesman, @steveliesman Andrew Ross Sorkin, @andrewrsorkin Becky Quick, @BeckyQuick Joe Kernen, @JoeSquawk Katie Kramer, @Kramer_Katie
NOW PLAYING
Private Credit Woes & Psychedelic Wins 4/20/26
No transcript for this episode yet